UNSPSC 51183407: Mitiglinide calcium hydrate

This classification denotes an anti-diabetic agent with the molecular formula 2C19H24NO3.Ca.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9651C21W3Z, chemically known as bis((2s)-2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionate) calcium dihydrate, d-, but more generally known as mitiglinide calcium hydrate, which bears US NIH Compound Identifier 6918235.

European Medicines Agency schedules mitiglinide calcium hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08999MIG. Most nations, for tariff purposes, schedule mitiglinide calcium hydrate under HS 29339990. SMILES: C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].O.O.[CA+2].

UNSPSC 51183407 Mitiglinide calcium hydrate is a Commodity code identifying a specific pharmaceutical active ingredient—a rapid-acting insulin secretagogue used to treat type 2 diabetes. State and local governments procure this substance primarily through pharmacy benefits managers, group purchasing organizations, and direct pharmaceutical suppliers as part of Medicaid formularies, state employee health plans, and corrections health services. The work involves sourcing, negotiating supply agreements, and managing inventory of this pharmaceutical compound rather than compounding, manufacturing, or formulation development.

The source provided contains no recent state or local contract opportunities under this code, limiting visibility into current issuing-body concentration, geographic spread, or representative recent solicitations. Procurement under pharmaceutical ingredient codes typically occurs through standing agreements with suppliers rather than individually posted RFPs or RFQs, and state purchasing offices often consolidate such buys through cooperative purchasing vehicles or group purchasing organizations where individual opportunities remain opaque. The lack of posted solicitation activity is consistent with pharmaceutical ingredient procurement practice at the state and local level.